Treatment with Kestose for inoperable pancreatic cancer

JRCT ID: jRCTs041180151

Registered date:29/03/2019

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Health Condition
• Date of first enrollment: 13/11/2019
• Target sample size: 40
• Study type: Interventional
• Intervention(s): Improvement of nutritional condition in the patients with inoperable pancreatic cancer

Outcome(s)

• Primary Outcome: Improvement of nutritional condition in the patients with inoperable pancreatic cancer

Secondary Outcome

1.Changes of Performance status(KPS)
2.Changes of The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire(EURTC-QLQ-C30)
3.Changes of total energy expenditure(TEE)
4.Changes of short-chain fatty acid(Butyric acid,Acetic acid,Prorionic acid etc.)
5.Changes of Rapid turnover protein
6.Correlation of gut microbiota and therapeutic effect
7.Metabolome,bile acid and protein analysis of metabolite in feces
8.Correlation between expiratory noble gases,gut microbiota and pancreatic cancer
9.Successful execution rate of Chemotherapy
10.Frequency and degree of side effect
11.Prognosis of inoperable pancreatic cancer

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both
• Include criteria: Patients diagnosed as unresectable pancreatic cancer

Exclude criteria

1.Women with pregnancy or possible pregnancy
2.Patients with severe renal failure and heart failure
3.Patient who is considered to be inappropriate for entry into the trial by the investigator
4.Patients with substantial alcohol consumption(20g/day for women or >30g/day for men
5.Patient who is poor in ingestion
6.Patient with other pancreas disease or other cancer
7.Patient who receive other treatments such as chemotherapy,radiotherapy and operation
8.Patients who take nonabsorbable antibiotics

Related Information

• Primary Sponsor: Honda Takashi
• Source(s) of Monetary Support: B Food Science Co., Ltd.